Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, today confirmed that free-floating DNA gleaned from blood is a key to early detection of colorectal cancer. Epigenomics showed that presence of the methylated form of DNA encoding the so-called Septin 9 gene is found in plasma of up to 57 percent of patients with all stages of colorectal cancer at high levels of specificity (95%). Data from the studies were presented at the 97th AACR Annual Meeting in Washington D.C., USA.
